Pharmaceutical distributor McKesson has asked a federal court in Philadelphia to dismiss more than 90 claims brought against it over the shingles vaccine Zostavax.

San Francisco-based McKesson, which is facing claims that it misrepresented the vaccine’s safety, filed a motion to dismiss Thursday in the U.S. District Court for the Eastern District of Pennsylvania, contending that 92 cases should be dismissed because the complaints failed to give sufficient details about the allegations.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]